MAPT and Alzheimer disease: Current diagnostic approaches for AD are mainly based on neuropsychological assessments, brain imaging, and the detection of β amyloid-1-42 peptide (Aβ42), total Tau protein, and hyperphosphorylated Tau protein (p-Tau) in cerebrospinal fluid (CSF) [74,75].